6-(4-(叔丁氧基羰基)哌嗪-1-基)-5-甲基吡啶-3-基硼酸 | 1379476-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 6-(4-(叔丁氧基羰基)哌嗪-1-基)-5-甲基吡啶-3-基硼酸
• 英文名称: (6-(4-(tert-butoxycarbonyl)piperazin-1-yl)-5-methylpyridin-3-yl)boronic acid
• 英文别名: (6-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-5-methylpyridin-3-yl)boronic acid；[5-methyl-6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyridin-3-yl]boronic acid
• CAS: 1379476-75-1
• 化学式: C₁₅H₂₄BN₃O₄
• 分子量: 321.184
• InChiKey: GHPCJQQHZGRNDJ-UHFFFAOYSA-N

物化性质

• 沸点：
  522.8±60.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.13
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  86.1
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  6-(4-(叔丁氧基羰基)哌嗪-1-基)-5-甲基吡啶-3-基硼酸 、 3-bromo-5-(methylsulfonyl)-4H-1,2,4-triazole 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl 4-[3-methyl-5-(5-methylsulfonyl-1H-1,2,4-triazol-3-yl)pyridin-2-yl]piperazine-1-carboxylate
  参考文献：
  名称：

  1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na V 1.7 inhibition

  摘要：

  Recently, the identification of several classes of aryl sulfonamides and acyl sulfonamides that potently inhibit Na(v)1.7 and demonstrate high levels of selectivity over other Na-v isoforms have been reported. The fully ionizable nature of these inhibitors has been shown to be an important part of the pharmacophore for the observed potency and isoform selectivity. The requirement of this functionality, however, has presented challenges associated with optimization toward inhibitors with drug-like properties and minimal off-target activity. In an effort to obviate these challenges, we set out to develop an orally bioavailable, selective Na(v)1.7 inhibitor, lacking these acidic functional groups. Herein, we report the discovery of a novel series of inhibitors wherein a triazolesulfone has been designed to serve as a bioisostere for the acyl sulfonamide. This work culminated in the delivery of a potent series of inhibitors which demonstrated good levels of selectivity over Na v 1.5 and favorable pharmacokinetics in rodents. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.04.035
• 作为产物：
  描述：

  N-Boc-哌嗪 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二甲基亚砜 为溶剂， 反应 44.0h， 生成 6-(4-(叔丁氧基羰基)哌嗪-1-基)-5-甲基吡啶-3-基硼酸
  参考文献：
  名称：

  [EN] MK2 DEGRADERS AND USES THEREOF
  [FR] AGENTS DE DÉGRADATION DE MK2 ET LEURS UTILISATIONS

  摘要：

  The present invention provides compounds, compositions thereof, and methods of using the same.

  公开号：

  WO2023278759A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS EZH2 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE EZH2
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015104677A1

  公开（公告）日：2015-07-16

  The present invention provides a compound of formula I, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

  本发明提供了一种I式化合物，或其同位素形式、立体异构体、互变异构体、药学上可接受的盐、溶剂合物、多晶形态、前药、N-氧化物或S-氧化物；以及它们的制备方法。本发明还涉及含有这些化合物的药物组合物，并其在治疗由EZH2（增强子饰同源物2）介导的疾病或疾病中的用途，尤其是癌症。
• 1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of Na V 1.7 inhibition
  作者：Alessandro A. Boezio、Kristin Andrews、Christiane Boezio、Margaret Chu-Moyer、Katrina W. Copeland、Erin F. DiMauro、Robert S. Foti、Robert T. Fremeau、Hua Gao、Stephanie Geuns-Meyer、Russell F. Graceffa、Hakan Gunaydin、Hongbing Huang、Daniel S. La、Joseph Ligutti、Bryan D. Moyer、Emily A. Peterson、Violeta Yu、Matthew M. Weiss

  DOI：10.1016/j.bmcl.2018.04.035

  日期：2018.6

  Recently, the identification of several classes of aryl sulfonamides and acyl sulfonamides that potently inhibit Na(v)1.7 and demonstrate high levels of selectivity over other Na-v isoforms have been reported. The fully ionizable nature of these inhibitors has been shown to be an important part of the pharmacophore for the observed potency and isoform selectivity. The requirement of this functionality, however, has presented challenges associated with optimization toward inhibitors with drug-like properties and minimal off-target activity. In an effort to obviate these challenges, we set out to develop an orally bioavailable, selective Na(v)1.7 inhibitor, lacking these acidic functional groups. Herein, we report the discovery of a novel series of inhibitors wherein a triazolesulfone has been designed to serve as a bioisostere for the acyl sulfonamide. This work culminated in the delivery of a potent series of inhibitors which demonstrated good levels of selectivity over Na v 1.5 and favorable pharmacokinetics in rodents. (C) 2018 Elsevier Ltd. All rights reserved.
• [EN] MK2 DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE MK2 ET LEURS UTILISATIONS
  申请人：[en]KYMERA THERAPEUTICS, INC.

  公开号：WO2023278759A1

  公开（公告）日：2023-01-05

  The present invention provides compounds, compositions thereof, and methods of using the same.